# MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy

> **NCT01851252** · PHASE1 · COMPLETED · sponsor: **Meridian Bioscience, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Chronic Liver Disease
- Cirrhosis
- Esophageal Varices
- Portal Hypertension
- Bleeding

## Interventions

- **DEVICE:** Methacetin (with Breath testing device)

## Key facts

- **NCT ID:** NCT01851252
- **Lead sponsor:** Meridian Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01851252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01851252, "MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01851252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*